What IDH Status Changes on a Brain Tumour Report

Medically reviewed by Dr. Michael Kachur · Frankfurt, Germany·

A brain tumor report reads like a verdict. There is a grade, usually a number between 2 and 4, and the eye goes straight to it. Below the grade sits a second block, shorter and stranger: IDH1, IDH2, 1p/19q, MGMT. Nobody explains that block. It gets read as supporting detail. It is not. In adult diffuse glioma the gene result often carries more weight than the grade printed above it, and the two lines only mean something read against each other, which is the kind of reading Healz was built to do.

Category
Health Insights
Date
Reading time
11 min
Share

This post walks the report from the top. What changed in 2021 and why the old names vanished, what an IDH mutation is, what 1p/19q codeletion adds, what MGMT methylation predicts and what it does not, and how a grade is now assigned with molecular findings in the room.

What IDH Status Changes on a Brain Tumour Report

Why the gene result sits under the grade

Until recently a glioma was named by what it looked like under a microscope. A pathologist read the cell shape, called it astrocytic or oligodendroglial, counted mitoses, and assigned a grade. Two people reading the same slide could land in different places.

The 2021 WHO classification of tumors of the central nervous system, the fifth edition, changed the basis of the name (Louis et al., Neuro-Oncology 2021). Adult-type diffuse gliomas are now defined by molecular markers, and the 15 entities the 2016 edition recognized collapse into three. Two familiar words went with them. Oligoastrocytoma, the mixed diagnosis, no longer exists as an entity, because those tumors sort cleanly into one group or the other once their molecular profile is known. And "anaplastic" is no longer the recommended word for a grade 3 tumor.

Ask Healz.

One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.

So a report written to the current scheme does not have a molecular appendix. The molecular result is part of the diagnosis. A report that still says anaplastic astrocytoma or oligoastrocytoma is either older than 2021 or written to the older framing, and that is worth knowing before anyone compares two reports side by side.

What an IDH mutation actually is

IDH stands for isocitrate dehydrogenase, an enzyme that does ordinary metabolic work in the cell. In glioma the gene is altered at a single spot: most commonly arginine 132 in IDH1, written R132H, and a matching position in IDH2. The change sits in the enzyme's active site, and the mutant enzyme stops doing its normal job and starts producing a different molecule, 2-hydroxyglutarate, which accumulates and alters how DNA across the whole genome is methylated.

That is the biology. The clinical consequence is blunt. Per the NCI, the presence of an IDH1 or IDH2 variant is a strong prognostic factor, and most grade 2 and grade 3 diffuse gliomas carry one; those patients live significantly longer than IDH-wildtype patients regardless of grade or histologic subtype. IDH status is the first fork in the classification, taken before anything else, because the gap in outlook between the two sides is wide enough that treating them as one disease makes no sense.

It has become a treatment target as well. In August 2024 the FDA approved vorasidenib for adults and patients 12 and older with grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation, after surgery, the first systemic therapy approved for that setting (FDA). A single line on a report now opens or closes that door. How these panels are ordered and what they can and cannot read is covered in our guide to tumor genomic testing.

The three types, and what separates them

Once IDH status is known, one more test splits the IDH-mutant side.

Astrocytoma, IDH-mutant. IDH mutation present, 1p/19q intact. Graded 2, 3 or 4.

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Both features are required. Graded 2 or 3. Of the three adult types this generally carries the most favorable outlook.

Glioblastoma, IDH-wildtype. No IDH mutation. Always grade 4. Under the current scheme glioblastoma means IDH-wildtype by definition, which is why an older report reading "IDH-mutant glioblastoma" does not map onto a current one; that tumor is now an IDH-mutant astrocytoma, grade 4.

The 1p/19q test looks for loss of the short arm of chromosome 1 together with the long arm of chromosome 19, a whole-arm codeletion that arises from an unbalanced translocation. The NCI calls it a powerful prognostic factor that may also predict response to chemotherapy. So the same IDH mutation leads to two different names and two different conversations depending on a second result that may come back a week later from a different lab.

How a grade is assigned now that molecules count

Grading is still partly histological. Nuclear atypia and mitotic activity push an IDH-mutant astrocytoma to grade 3; microvascular proliferation or necrosis push it to grade 4. What is new is that molecular findings can set the grade on their own.

An IDH-mutant astrocytoma with homozygous deletion of CDKN2A or CDKN2B is graded 4 even with no high-grade features on the slide, because that deletion behaves as an independent negative prognostic factor. On the other side, an IDH-wildtype diffuse glioma with a TERT promoter mutation, EGFR amplification, or gain of chromosome 7 with loss of chromosome 10 is diagnosed as glioblastoma, grade 4, again without high-grade histology.

Two things follow. A grade 4 can now be assigned from a molecular panel rather than from what the tissue looks like, so a reassuring-sounding slide report and a grade 4 diagnosis are not a contradiction. And grading is now done within a tumor type rather than across all of them, so grade 3 in an oligodendroglioma and grade 3 in an astrocytoma are not the same statement about the future.

What MGMT promoter methylation predicts, and what it does not

MGMT is a DNA repair gene. When its promoter is methylated the gene is switched down, the tumor repairs alkylating damage less well, and alkylating chemotherapy such as temozolomide has an easier target.

The NCI states that methylation of the MGMT promoter is an independent prognostic factor for improved survival in newly diagnosed glioblastoma, and that it may predict response to temozolomide, while noting the evidence for it as a predictive rather than prognostic marker is less certain. Prognostic means the methylated group does better. Predictive means the methylation is what makes the drug work. The first is well established; the second is still argued over. The US NCCN guidelines have incorporated MGMT promoter status into adjuvant therapy guidance.

Unlike IDH and 1p/19q, MGMT does not change the tumor's name. It sits in the treatment conversation, which is why it often appears on a separate page or arrives after the diagnosis is already settled.

Where the MRI helps and where it stops

Imaging is read before any tissue exists, and it can hint at molecular status. What sends someone for that first scan is a separate subject, covered in our piece on brain tumor headache red flags. The best-studied example is the T2-FLAIR mismatch sign, a tumor that is uniformly bright on T2 but dark through most of its center on FLAIR. A 2021 meta-analysis of 12 studies covering 1,053 patients found the sign pooled 100% specificity and 42% sensitivity for IDH-mutant, 1p/19q non-codeleted astrocytoma, and a 2018 validation study in Neuro-Oncology reported the same pattern across 154 scans: specificity 100%, sensitivity 51%.

Read that honestly and it says one thing clearly. When the sign is there, the tumor is almost certainly an IDH-mutant astrocytoma. When it is absent, which is most of the time, the scan has said nothing about IDH either way. This is the general shape of ai mri analysis and online mri report analysis ai on glioma: imaging narrows the question and does not answer it. The molecular answer comes from tissue.

How Healz reads the grade, the molecular result and the MRI against each other

A glioma report does not arrive as a report. The MRI lands first. The grade follows after surgery or biopsy. The molecular panel arrives weeks later, often from a different lab, sometimes in a different portal. Each page gets read once, on the day it shows up, and the meaning sits between them.

Healz is equipped with memory, and it does three things by design: it pulls the medical facts out of every report you upload, dates each one, and keeps the IDH result, the 1p/19q status, the MGMT line and the grade together, so the molecular panel is read beside the MRI and the histology it belongs to rather than months apart from both. A folder of PDFs holds the same documents and connects nothing.

The rest of the case sits in the same chat. Frontier AI works the whole file, so as a pathology report ai and an ai oncology layer, Healz reads the molecular block against the grade, the imaging and the earlier scans together. Healz is equipped with root-cause technology, which is why it cross-checks the case against more than a million rare cases and questions a label that does not fit the molecular picture instead of accepting it. Everything is in one place, one chat, not ten apps and three portals. You can bring a board-certified doctor into the same chat for a second opinion.

Frequently asked questions

What does IDH mutant mean on a brain tumor report?

It means the tumor carries a variant in the IDH1 or IDH2 gene, usually at arginine 132 in IDH1. Per the NCI, that is a strong prognostic factor, and IDH-mutant gliomas carry significantly longer survival than IDH-wildtype ones regardless of grade or histologic subtype. Under the 2021 WHO classification it is also the first branch point in naming the tumor.

Is IDH mutant glioma better than IDH wildtype?

The outlook is substantially better, which is why the 2021 classification separates them rather than grading them on one scale. An IDH-wildtype adult diffuse glioma that meets the molecular or histological criteria is glioblastoma, grade 4. IDH-mutant tumors span grades 2 to 4.

What does 1p/19q codeletion mean?

It means the short arm of chromosome 1 and the long arm of chromosome 19 have both been lost. Found together with an IDH mutation, it makes the diagnosis oligodendroglioma rather than astrocytoma. The NCI describes it as a powerful prognostic factor that may also predict response to chemotherapy.

Does MGMT methylation change the diagnosis?

No. MGMT promoter methylation does not alter what the tumor is called; IDH status and 1p/19q do that. The NCI calls MGMT methylation an independent prognostic factor for improved survival in newly diagnosed glioblastoma and notes it may predict response to temozolomide, with the predictive evidence less settled than the prognostic.

Why does my report say anaplastic astrocytoma or oligoastrocytoma?

Those names come from the pre-2021 framing. The 2021 WHO classification dropped "anaplastic" as the term for a grade 3 tumor, and oligoastrocytoma no longer exists as an entity because those tumors sort into one of the three molecularly defined types. An older report is not wrong; it was written to a different scheme, and the two do not translate line for line.

The grade is the line that gets read, and the gene result underneath it is the line that changes the most. Neither one says much alone. What a current glioma report actually is, is three findings that have to be held together, and holding them together over months, across labs and portals and a scan nobody has reopened since spring, is the whole job.

Written by Healz Team · Filed under Health Insights

Your health deserves more than guesswork

Get a real investigation, not a symptom list. Root causes found, history remembered, dots connected.

Not a medical provider. Healz.ai is an educational service. Always discuss every decision with your doctor. AI can make mistakes.

© 2026 HealzAI Inc1111B S Governors Ave #92123, Dover, DE 19904, USAMade with for better health